Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Palladio
5 Walnut Grove Drive, Suite 120
Horsham, PA 19044
http://www.palladiobeauty.com/

Palladio Biosciences is a privately-held, clinical stage biopharmaceutical company developing medicines for orphan diseases of the kidney. Palladio is developing its lead drug, lixivaptan, for Autosomal Dominant Polycystic Kidney Disease (ADPKD), an orphan kidney disease for which there are limited treatment options. Lixivaptan is a potent, selective vasopressin V2 receptor antagonist, a mechanism of action that has clinical proof of concept to slow kidney function decline in adults at risk of rapidly progressing ADPKD. It has successfully completed a Phase 2 clinical trial, The ELiSA Study, in patients with ADPKD, and has also been successfully administered to a patient who had previously been unable to take tolvaptan due to liver enzyme increases under an expanded access program. Lixivaptan is for investigational use only.

Key Contact
Name
Alex Martin
Title
CEO
E-Mail
Funding Events

Date
Amount
Type
Investors
09/25/20 $20,000,000 Series B Medicxi
Osage University Partners
Roche Venture Fund
Samsara BioCapital


Featured Reading